Furthermore, combining ibrutinib with the BCL‐2 inhibitor venetoclax is a proven and successful treatment option in CLL (Hillmen et al., 2019; Kater et al., 2019), yet resistance can still arise from strong activation of the NF‐κB pathway via microenvironmental agonists such as CD40L and CpG oligodeoxynucleotides (Jayappa et al., 2017). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.